中文摘要：

目的分析70例慢性粒细胞白血病（CML）的治疗现状。方法回顾分析1998年4月至2014年3月起病的70例患者的临床资料及治疗反应。结果全部为Ph染色体阳性CML,男女性各35例,中位年龄50岁。70例患者中,使用酪氨酸激酶抑制剂（TKI）伊马替尼、干扰素和羟基脲的患者分别占35.7%、35.7%和52.9%,接受异基因造血干细胞移植（allo-HSCT）的患者占11.4%。随访时间从4月至16年,中位随访27个月。TKI治疗组3年总生存（OS）率是85.7%,而羟基脲（和/或）干扰素组及异基因造血干细胞移植病人3年OS率分别是46.4%和75.0%,与TKI治疗组比较的P值分别是0.04和0.19。结论 CML是一种骨髓增殖性疾病,随着TKI作为一线治疗用药的越来越广泛的临床应用,使得CML患者的治疗效果和生存质量均得到明显改善。

英文摘要：

Objective To investigate the clinical characteristics and treatment response of 70 patients with chronic myeloid leukemia（ CML）. Methods Clinical data,treatment efficacy and outcomes of 70 cases of CML enrolled from April 1998 to March 2014 were retrospectively analyzed. Results All the patients were Ph chromosome positive. Median age of onset were 50 years old. Male and female were 35 patients respectively. Of all 70 patients with the treatment of tyrosine-kinase inhibitor,interferon-alpha and hydroxyurea treatment account for 35. 7%,35. 7% and 52. 9%,respectively. The allogeneic hematopoietic stem cell transplantation（ allo-HSCT） account for 11. 4%. The time of follow up is from 4 months to 16 years. The median follow up time is 27 months. 3 year overall survival rate（ OS） was 85. 7% in TKI treatment group.3 years OS rates in hydroxyurea and interferon group were 46. 4% and 75%,respectively. Compared with TKI group,p value were 0. 04 and 0.19 in the interferon and hydroxyurea group. Conclusion CML is a myeloproliferative disorder of hematopoietic stem cells. TKIs are now the first line of treatment for CML. Therefore,the treatment for CML changed significantly.